P
Phillip A. Dennis
Researcher at Johns Hopkins University School of Medicine
Publications - 100
Citations - 13820
Phillip A. Dennis is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Protein kinase B & PI3K/AKT/mTOR pathway. The author has an hindex of 46, co-authored 100 publications receiving 12997 citations. Previous affiliations of Phillip A. Dennis include National Institutes of Health & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes
Daniel J. Klionsky,Hagai Abeliovich,Patrizia Agostinis,Devendra K. Agrawal,Gjumrakch Aliev,David S. Askew,Misuzu Baba,Eric H. Baehrecke,Ben A. Bahr,Andrea Ballabio,Bruce A. Bamber,Diane C. Bassham,Ettore Bergamini,Xiaoning Bi,Martine Biard-Piechaczyk,Janice S. Blum,Dale E. Bredesen,Jeffrey L. Brodsky,John H. Brumell,Ulf T. Brunk,Wilfried Bursch,Nadine Camougrand,Eduardo Cebollero,Francesco Cecconi,Yingyu Chen,Lih-Shen Chin,Augustine M.K. Choi,Charleen T. Chu,Jongkyeong Chung,Peter G.H. Clarke,Robert S. B. Clark,Steven Clarke,Corinne Clavé,John L. Cleveland,Patrice Codogno,María Isabel Colombo,Ana Coto-Montes,James M. Cregg,Ana Maria Cuervo,Jayanta Debnath,Francesca Demarchi,Patrick B. Dennis,Phillip A. Dennis,Vojo Deretic,Rodney J. Devenish,Federica Di Sano,J. Fred Dice,Marian DiFiglia,Savithramma P. Dinesh-Kumar,Clark W. Distelhorst,Mojgan Djavaheri-Mergny,Frank C. Dorsey,Wulf Dröge,Michel Dron,William A. Dunn,Michael Duszenko,N. Tony Eissa,Zvulun Elazar,Audrey Esclatine,Eeva-Liisa Eskelinen,László Fésüs,Kim D. Finley,José M. Fuentes,Juan Fueyo,Kozo Fujisaki,Brigitte Galliot,Fen-Biao Gao,David A. Gewirtz,Spencer B. Gibson,Antje Gohla,Alfred L. Goldberg,Ramon Gonzalez,Cristina González-Estévez,Sharon M. Gorski,Roberta A. Gottlieb,Dieter Häussinger,You-Wen He,Kim A. Heidenreich,Joseph A. Hill,Maria Høyer-Hansen,Xun Hu,Wei-Pang Huang,Akiko Iwasaki,Marja Jäättelä,William T. Jackson,Xuejun Jiang,Shengkan Jin,Terje Johansen,Jae U. Jung,Motoni Kadowaki,Chanhee Kang,Ameeta Kelekar,David Kessel,Jan A.K.W. Kiel,Pyo Kim Hong,Adi Kimchi,Timothy J. Kinsella,Kirill Kiselyov,Katsuhiko Kitamoto,Erwin Knecht,Masaaki Komatsu,Eiki Kominami,Seiji Kondo,Attila L. Kovács,Guido Kroemer,Chia Yi Kuan,Rakesh Kumar,Mondira Kundu,Jacques Landry,Marianne M. Laporte,Weidong Le,Huan Yao Lei,Michael J. Lenardo,Beth Levine,Andrew P. Lieberman,Kah-Leong Lim,Fu-Cheng Lin,Willisa Liou,Leroy F. Liu,Gabriel Lopez-Berestein,Carlos López-Otín,Bo Lu,Kay F. Macleod,Walter Malorni,Wim Martinet,Ken Matsuoka,Josef Mautner,Alfred J. Meijer,Alicia Meléndez,Paul A.M. Michels,Giovanni Miotto,Wilhelm P. Mistiaen,Noboru Mizushima,Baharia Mograbi,Iryna Monastyrska,Michael Moore,Paula I. Moreira,Yuji Moriyasu,Tomasz Motyl,Christian Münz,Leon Murphy,Naweed I. Naqvi,Thomas P. Neufeld,Ichizo Nishino,Ralph A. Nixon,Takeshi Noda,Bernd Nürnberg,Michinaga Ogawa,Nancy L. Oleinick,Laura J. Olsen,Bulent Ozpolat,Shoshana Paglin,Glen E. Palmer,Issidora S. Papassideri,Miles Parkes,David H. Perlmutter,George Perry,Mauro Piacentini,Ronit Pinkas-Kramarski,Mark Prescott,Tassula Proikas-Cezanne,Nina Raben,Abdelhaq Rami,Fulvio Reggiori,Bärbel Rohrer,David C. Rubinsztein,Kevin M. Ryan,Junichi Sadoshima,Hiroshi Sakagami,Yasuyoshi Sakai,Marco Sandri,Chihiro Sasakawa,Miklós Sass,Claudio Schneider,Per Ottar Seglen,Oleksandr Seleverstov,Jeffrey Settleman,John J. Shacka,Irving M. Shapiro,Andrei A. Sibirny,Elaine C.M. Silva-Zacarin,Hans-Uwe Simon,Crisfiano Simone,Anne Simonsen,Mark A. Smith,Katharina Spanel-Borowski,Vickram Srinivas,Meredith A. Steeves,Harald Stenmark,Per E. Stromhaug,Carlos S. Subauste,Seiichiro Sugimoto,David Sulzer,Toshihiko Suzuki,Michele S. Swanson,Ira Tabas,Fumihiko Takeshita,Nicholas J. Talbot,Zsolt Tallóczy,Keiji Tanaka,Kozo Tanaka,Isei Tanida,Graham S. Taylor,J. Paul Taylor,Alexei Terman,Gianluca Tettamanti,Craig B. Thompson,Michael Thumm,Aviva M. Tolkovsky,Sharon A. Tooze,Ray Truant,Lesya V. Tumanovska,Yasuo Uchiyama,Takashi Ueno,Néstor L. Uzcátegui,Ida J. van der Klei,Eva C. Vaquero,Tibor Vellai,Michael W. Vogel,Hong Gang Wang,Paul Webster,John W. Wiley,Zhijun Xi,Gutian Xiao,Joachim Yahalom,Jin Ming Yang,George S. Yap,Xiao Ming Yin,Tamotsu Yoshimori,Li Yu,Zhenyu Yue,Michisuke Yuzaki,Olga Zabirnyk,Xiaoxiang Zheng,Xiongwei Zhu,Russell L. Deter +235 more
TL;DR: A set of guidelines for the selection and interpretation of the methods that can be used by investigators who are attempting to examine macroautophagy and related processes, as well as by reviewers who need to provide realistic and reasonable critiques of papers that investigate these processes are presented.
Journal Article
Akt/Protein Kinase B Is Constitutively Active in Non-Small Cell Lung Cancer Cells and Promotes Cellular Survival and Resistance to Chemotherapy and Radiation
TL;DR: Akt/PKB is identified as a constitutively active kinase that promotes survival of NSCLC cells and modulation of Akt/P KB activity by pharmacological or genetic approaches alters the cellular responsiveness to therapeutic modalities typically used to treat patients withNSCLC.
Journal ArticleDOI
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations
TL;DR: This review will provide an update on the clinical progress of various agents that target the PI3K/Akt/mTOR pathway and discuss strategies to combine these pathway inhibitors with conventional chemotherapy, radiotherapy, as well as newer targeted agents.
Journal ArticleDOI
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
TL;DR: StudyingPTEN in the continuum of rare syndromes, common cancers and mouse models provides insight into the role of PTEN in tumorigenesis and will inform targeted drug development.
Journal Article
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
TL;DR: It is shown that endogenous Akt activity promotes breast cancer cell survival and therapeutic resistance, and that induction of Akt by chemotherapy, trastuzumab, or tamoxifen might be an early compensatory mechanism that could be exploited to increase the efficacy of these therapies.